KAICO

KAICO is a Japanese biotechnology company that utilizes a proprietary silkworm-baculovirus expression system to produce high-value recombinant proteins. Spun out from Kyushu University, the company leverages the natural protein-folding capabilities of silkworms to create complex proteins that are often difficult to express in traditional cell lines. Their primary business focus includes the development of oral vaccines for both animal and human health, as well as the production of diagnostic reagents and research proteins. KAICO's platform offers a scalable and cost-effective alternative to conventional bioreactors, particularly for membrane proteins and glycoproteins. The company has successfully commercialized diagnostic components for COVID-19 and is advancing a pipeline of veterinary vaccines.